N-(3-acetyl-2-hydroxyphenyl)-4-(4-phenylbutoxy)benzamide

We are N-(3-acetyl-2-hydroxyphenyl)-4-(4-phenylbutoxy)benzamide CAS:136450-06-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:   N-(3-acetyl-2-hydroxyphenyl)-4-(4-phenylbutoxy)benzamide
CAS.NO:  136450-06-1
Synonyms:
3'-[4-(4-Phenylbutoxy)benzoylamino]-2'-hydroxyacetophenone
N-(3-Acetyl-2-hydroxyphenyl)-4-(4-phenylbutoxy)benzamide
N-(3-Acetyl-2-hydroxyphenyl)-4-(4-phenylbutoxy)benzolcarboxamid
Benzamide, N-(3-acetyl-2-hydroxyphenyl)-4-(4-phenylbutoxy)-

Molecular Formula: C25H25NO4
Molecular Weight:  403.47000

Physical and Chemical Properties:
Density: 1.213g / cm3
Boiling point: 528ºC at 760mmHg
Flash point: 273.2ºC
Refractive index: 1.626

Specification:
Appearance: White powder
Purity:≥99.0%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application: 
 Intermediates of ranlukast CAS:103177-37-3.

N-(3-acetyl-2-hydroxyphenyl)-4-(4-phenylbutoxy)benzamide


Related News: Large pharmaceutical companies are investing a disproportionately large amount of annual revenue in research and development (R&D), according to GlobalData’s Company Financials database.2,6-Dimethylphenol CAS:576-26-1 “With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.”433-19-2 In 2016, the export volume of China’s specialty drug substances reached US $ 3.53 billion, accounting for 13.8% of the total drug substances.dimetil-bis [[metil (difenil) silil] oxi] silano CAS:3982-82-9 Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance.Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.

Related Products
Product Name
2,3-Difluorophenyl butyl ether View Details
2-[2-(4-chlorophenoxy)phenyl]acetic acid View Details
L-Glutamic acid 5-methyl ester View Details
trans,trans-2,4-Heptadienal manufacturer trans-Hexahydroisobenzofuran-1,3-dione manufacturer N6-Benzoyladenosine manufacturer N-Methyl acetoacetamide manufacturer (3S,4R)-4-Acetoxy-3-[(R)-1-(tert-butyldimethylsilyloxy)ethyl]azetidin-2-one manufacturer